Skip to content

Study · Not a test of the peptide alone · 2018

5 results

Analysis of new growth promoting black market products.

Krug O, Thomas A, Malerød-Fjeld H, Dehnes Y, Laussmann T, Feldmann I, Sickmann A, Thevis M

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society19 May 2018Cited by 9 (Europe PMC)

PMID29864719 (opens in a new tab)DOI10.1016/j.ghir.2018.05.001 (opens in a new tab)PepBankPUB-29864719
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01LabNot a test of GHRP-6 aloneIn vitro (cell-free)Other

    Mass spectrometry identified Gly-GHRP‑6, GHRP‑6 extended by an N-terminal glycine, among three GHRP analogues in black market products.

    In plain wordsLab analysis of black market products found a GHRP‑6 form with one extra glycine at one end.

    Peptide
    GHRP-6
    Outcome
    Not applicableGly-GHRP-6 identified in black market products
    Study

    n: not reported in source

    Black market products analysed by mass spectrometry
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Additionally, three analogues of GHRPs were identified as Gly-GHRP-6, Gly-GHRP-2 and Gly-Ipamorelin, representing the corresponding GHRP extended by a N-terminal glycine residue.
    1 context sentence
    Summary · context
    The structure of these peptides was characterised by means of high resolution (tandem) mass spectrometry, and for Gly-Ipamorelin and Gly-GHRP-2 their identity was additionally confirmed by custom synthesis.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 02LabNot a test of GHRP-2 aloneIn vitro (cell-free)Other

    Mass spectrometry identified Gly-GHRP‑2, GHRP‑2 extended by an N-terminal glycine residue, among black market products.

    In plain wordsIn lab tests, a black market product contained a version of GHRP‑2 with an extra glycine at one end.

    Peptide
    GHRP-2
    Outcome
    Not applicableIdentification of Gly-GHRP-2 in black market products
    Study

    n: not reported in source

    black market products
    Outcome group
    Analytical methods and detection · Pharmacology

    Source sentences

    Summary
    Additionally, three analogues of GHRPs were identified as Gly-GHRP-6, Gly-GHRP-2 and Gly-Ipamorelin, representing the corresponding GHRP extended by a N-terminal glycine residue.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  3. 03LabNot a test of GHRP-2 aloneIn vitro (cell-free)Other

    High resolution tandem mass spectrometry characterised the structure of Gly-GHRP‑2, and custom synthesis confirmed its identity.

    In plain wordsIn lab tests, mass spectrometry and a synthesised copy confirmed the structure of Gly-GHRP‑2.

    Peptide
    GHRP-2
    Outcome
    Not applicableStructure confirmation of Gly-GHRP-2
    Study

    n: not reported in source

    black market products
    Outcome group
    Analytical methods and detection · Pharmacology

    Source sentences

    Summary
    The structure of these peptides was characterised by means of high resolution (tandem) mass spectrometry, and for Gly-Ipamorelin and Gly-GHRP-2 their identity was additionally confirmed by custom synthesis.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  4. 04LabNot a test of Ipamorelin aloneOther designOther

    Gly-Ipamorelin, ipamorelin extended by an N-terminal glycine residue, was identified among new growth promoting black market products.

    In plain wordsIn lab tests, a black market product was found to contain ipamorelin with an extra glycine at the start of the chain.

    Peptide
    Ipamorelin
    Outcome
    Not applicableIdentification of Gly-Ipamorelin in black market products
    Study

    n: not reported in source

    Outcome group
    Analytical methods and detection · Pharmacology

    Source sentences

    Summary
    three analogues of GHRPs were identified as Gly-GHRP-6, Gly-GHRP-2 and Gly-Ipamorelin, representing the corresponding GHRP extended by a N-terminal glycine residue

    In this study, Ipamorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Ipamorelin.

  5. 05LabNot a test of Ipamorelin aloneOther designOther

    The identity of Gly-Ipamorelin was confirmed by custom synthesis after structural characterisation by high resolution tandem mass spectrometry.

    In plain wordsIn lab tests, a custom-made copy of Gly-Ipamorelin confirmed the structure found in the black market product.

    Peptide
    Ipamorelin
    Outcome
    Not applicableStructure of Gly-Ipamorelin confirmed by custom synthesis
    Study

    n: not reported in source

    Outcome group
    Analytical methods and detection · Pharmacology

    Source sentences

    Summary
    for Gly-Ipamorelin and Gly-GHRP-2 their identity was additionally confirmed by custom synthesis.
    1 context sentence
    Summary · context
    The structure of these peptides was characterised by means of high resolution (tandem) mass spectrometry

    In this study, Ipamorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Ipamorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 22 to 45Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 24 times, first on 13 Oct 2026, 21:43 UTC. The status did not change between them.

    Study results updated

  2. Version 21

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Versions 3 to 20

    13 Oct 2026, 14:22 UTC

    The same notice was added 18 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  4. Version 2

    9 Oct 2026, 03:13 UTC

    Study data updated · source update from Europe PMC

  5. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.